Perioperative Management of Femur Fracture with IHD Post-PCI on Dual Antiplatelet Therapy
In this trauma patient requiring urgent femur fracture surgery while on aspirin and clopidogrel after PCI, continue aspirin perioperatively and stop clopidogrel 5 days before surgery if the stent is >6-12 months old; if the stent is <6-12 months old, maintain both agents and proceed to surgery immediately given the life-threatening nature of the femur fracture. 12
Critical Initial Assessment
Immediately determine:
- Timing of PCI and stent type (bare metal vs drug-eluting)
- Time since stent placement (most critical factor)
- Bleeding risk of femur surgery (intermediate-to-major hemorrhagic risk)
- Risk factors for stent thrombosis (diabetes, multiple stents, bifurcation lesions, incomplete revascularization, low ejection fraction) 2
Management Algorithm Based on Stent Timing
If Stent Placed <30 Days (BMS) or <6-12 Months (DES):
This is the highest-risk scenario for stent thrombosis. 12
- Continue BOTH aspirin and clopidogrel through surgery 22
- Do NOT delay surgery - femur fractures require urgent fixation (ideally <24 hours) to reduce mortality and morbidity 34
- Accept increased bleeding risk as the alternative (stent thrombosis) carries 45% mortality 1
- Have tranexamic acid and platelet concentrates available 3
- Restart clopidogrel immediately postoperatively with 300mg loading dose 22
If Stent Placed >6-12 Months (DES) or >30 Days (BMS):
This represents moderate thrombotic risk. 22
- Continue aspirin perioperatively (this is the preferred strategy) 222
- Stop clopidogrel 5 days before surgery (compromise between platelet half-life and thrombosis risk) 22
- Restart clopidogrel within 24-48 hours postoperatively with 300mg loading dose 22
- Surgery should still occur urgently, ideally within 24 hours of stopping clopidogrel 3
Multidisciplinary Team Meeting
Before proceeding, convene an urgent discussion including: 22
- Cardiologist (assess stent thrombosis risk)
- Orthopedic surgeon (assess bleeding risk and surgical urgency)
- Anesthesiologist (anesthetic plan, neuraxial vs general)
- Hematologist if available
Document the agreed plan clearly in the medical record. 2
Anesthetic Considerations
- Neuraxial anesthesia is SAFE with aspirin alone 3
- Neuraxial anesthesia is CONTRAINDICATED with dual antiplatelet therapy (risk of spinal hematoma)
- Use general anesthesia if continuing both agents 3
Critical Pitfalls to Avoid
DO NOT delay surgery beyond 24 hours - the 2011 study showed patients on clopidogrel with delayed surgery (mean 8 days) had 25.9% medical complications and 14.8% mortality, compared to 18% complications and 11% mortality in matched controls operated at 2.3 days 4. The mortality difference, while not statistically significant in that small study, demonstrates the danger of prolonged delays.
DO NOT use bridging therapy with LMWH or unfractionated heparin - this increases bleeding risk without proven benefit in preventing stent thrombosis, and heparin rebound can paradoxically increase thrombotic risk 123
DO NOT stop aspirin - the 2014 ACC/AHA guidelines emphasize that aspirin should be continued in patients with previous coronary stenting when cardiac event risk outweighs bleeding risk 1, and the French Task Force specifically recommends maintaining aspirin regardless of when the stent was placed 22
Postoperative Management
- Resume clopidogrel as soon as hemostasis is secure (typically 24-48 hours) 23
- Consider 300mg loading dose to rapidly restore platelet inhibition 22
- Continue aspirin without interruption
- Monitor for both bleeding complications and cardiac events
- Maintain VTE prophylaxis with mechanical measures initially
Evidence Strength and Nuances
The 2014 ACC/AHA guideline 1 is the most authoritative source but acknowledges limited prospective data. The POISE-2 trial showed aspirin increased bleeding without reducing cardiac events, but excluded patients within 1 year of DES placement - precisely the highest-risk population in this case. The French Task Force recommendations 2222222, while older (2006), provide the most specific algorithmic approach to this exact clinical scenario and remain widely cited.
Recent evidence 3 from 2024 supports early surgery without discontinuing antiplatelet therapy in femur fractures, with antifibrinolytic therapy and platelet transfusion reserved for significant bleeding.
The fundamental principle: in trauma requiring urgent surgery, the risk of delaying surgery typically exceeds the risk of bleeding, especially given modern hemostatic techniques.